Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported routine equity compensation activity involving restricted stock units and common stock. On June 15, 2026, 1,402 restricted stock units were converted into an equal number of common shares as part of a previously granted award that vested over a three-year period.
To cover related tax obligations on this vesting, the company retained 594 common shares at a price of $129.82 per share, a non-market tax-withholding disposition rather than an open-market sale. Following these transactions, Freeman directly held 61,101 common shares of Guardant Health.
Guardant Health, Inc.’s Chief Financial Officer Michael Brian Bell reported routine equity compensation activity. On June 15, 2026, 2,039 Restricted Stock Units were converted into an equal number of shares of common stock, reflecting the vesting schedule of an award granted on June 9, 2023.
On the same date, 1,096 shares of common stock were withheld by the company to cover Mr. Bell’s tax withholding obligations tied to this vesting, with the shares valued at $129.82 each. After these transactions, Mr. Bell directly owned 48,452 shares of Guardant Health common stock.
Guardant Health (GH) notice of proposed insider sales by Musa Tariq. The filing lists prior sales of common stock in three separate transactions: 03/18/2026 — 348 shares (aggregate $30,655), 04/16/2026 — 116 shares (aggregate $9,840), and 05/18/2026 — 116 shares (aggregate $11,131).
The filing also records a restricted stock lapse on 06/15/2026 associated with equity compensation and lists brokerage details for Charles Schwab & Co. The notice records proposed sale activity under Form 144; timing and method of any future sales are not detailed beyond the listed items.
Guardant Health, Inc. Chief Information Officer Kumud Kalia reported an open-market sale of 3,418 shares of Common Stock on June 11, 2026 at an average price of $130.2386 per share. After this transaction, Kalia directly holds 41,090 shares, indicating he retains a substantial ongoing equity stake.
GH affiliate reported a proposed sale of 5,000 shares of Common Stock by Kumud Kalia on 06/10/2026, with a reported gross value of $652,030.00. The filing lists prior open-market purchases of 2,231 shares on 06/09/2023 and 2,187 shares on 03/18/2024.
GH affiliate filing amends a prior Form 144. The filing reports a sale of 5,000 shares on 06/10/2026 for $652,030 and lists 600 shares purchased on 06/09/2023 via open-market purchase. The broker on record is Fidelity Brokerage Services LLC.
Form 144 notice of proposed sales by Kumud Kalia and a prior purchase record. The filing lists sales by Kumud Kalia of 6,839 shares on 03/15/2026 for $584,666.00, 5,092 shares on 04/01/2026 for $464,135.80, and 5,000 shares on 06/10/2026 for $652,030.00. The record also shows Fidelity Brokerage Services LLC purchased 600 shares in an open-market purchase on 06/09/2023.
Guardant Health, Inc. Chief Information Officer Kumud Kalia reported an open-market sale of 5,000 shares of Common Stock. The shares were sold at a price of $130.406 per share. After this transaction, Kalia directly owns 44,508 shares, indicating a remaining substantial equity position.
Guardant Health, Inc. Co-Chief Executive Officer Helmy Eltoukhy reported a series of open-market sales of the company’s common stock on June 5, 2026. Through the Helmy A. Eltoukhy Revocable Trust, he sold a total of 100,000 shares in seven transactions at weighted average prices between about $124.95 and $132.55 per share. Following these sales, the trust continues to hold approximately 2,012,919 shares of Guardant Health common stock indirectly attributed to Eltoukhy.